Morgan Stanley raised the firm’s price target on Roche to CHF 260 from CHF 250 and keeps an Underweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Fresenius SE launches biosimilar of Roche’s Actemra
- Genentech announces STARGLO study meets primary endpoint
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer’s disease diagnosis